옵션 체인은 다양한 행사가격과 만기일에 대한 Veren의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Veren에 대한 시장 심리를 평가합니다..

Veren (NYSE:VRN) 주식, 옵션 체인

Veren

Veren Inc is an oil producer company. It is engaged in acquiring, developing, and holding interests in petroleum assets operations across western Canada.

D-Wave Quantum Inc.

Equities

Mid Cap

News

Movers

Trading Ideas

HSAI

IONQ

ORLA

PTGX

QBTS

RGTI

SMTC

이 중형주들은 지난주에 가장 좋은 성과를 냈습니다. 당신의 포트폴리오에 있나요? 1. D-웨이브 퀀텀(NYSE:QBTS)의 주식은 회사가 4분기 수주가 1억 8,300만 달러로 전년 대비 502% 증가했다고 보고한 후 95.95% 상승했다.

D-웨이브 퀀텀과 아이온큐 등 지난주 급등한 중형주 8종목 (3월 10일-3월 14일)

Veren Inc

Verona Pharma plc - American Depositary Shares

Verona Pharma PLC

VERANO HLDGS CORP by Verano Holdings Corp.

Verano Holdings Corp

Varonis Systems Inc

Verint Systems Inc

<p>Guggenheim  analyst Michael Schmidt   reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $109 price target.</p>


Price Target

Reiteration

Analyst Ratings

MRUS

Guggenheim Reiterates Buy on Merus, Maintains $109 Price Target

<p>Truist Securities  analyst Michael Lewis   maintains Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>) with a Hold and raises the price target from $38 to $39.</p>


Truist Securities Maintains Hold on Omega Healthcare Invts, Raises Price Target to $39

<p>Truist Securities  analyst Srikripa Devarakonda   maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Hold and lowers the price target from $74 to $72.</p>


INCY

Truist Securities Maintains Hold on Incyte, Lowers Price Target to $72

<p>Guggenheim  analyst Joseph Osha   reiterates Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) with a Buy and maintains $7 price target.</p>


EOSE

Guggenheim Reiterates Buy on Eos Energy Enterprises, Maintains $7 Price Target

<p>Truist Securities  analyst Richard Newitter   maintains Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) with a Hold and lowers the price target from $90 to $82.</p>


GMED

Truist Securities Maintains Hold on Globus Medical, Lowers Price Target to $82

WIIM

XPEV

XPeng shares are trading lower after the company reported a Q4 Adj EPS miss.

<p>Guggenheim  analyst John Difucci   maintains Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) with a Buy and raises the price target from $76 to $80.</p>


RBRK

Guggenheim Maintains Buy on Rubrik, Raises Price Target to $80

<p>Truist Securities  analyst Jailendra Singh   maintains Astrana Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTH#NASDAQ">ASTH</a>) with a Buy and lowers the price target from $50 to $46.</p>


ASTH

Truist Securities Maintains Buy on Astrana Health, Lowers Price Target to $46

<p>Earlier this month, Sycamore Partners agreed to acquire <strong>Walgreens Boots Alliance Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) for $11.45 per share <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">in cash at closing</a>. Shareholders are also eligible to receive up to $3 in cash per share from the future monetization of Walgreens&#8217; debt and equity interests in VillageMD, which includes the Village Medical, <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44182479/walgreens-stock-rises-as-company-inks-10b-deal-to-go-private" target="_blank" rel="noreferrer noopener">Summit Health and CityMD businesses</a>.</p>
<p>Soon after, <strong>Gary Black</strong>, managing partner at <strong>The Future Fund LLC</strong>, said, &#8220;I&#8217;ve talked before about how this company shouldn&#8217;t be public,&#8221; adding that the move is driven by its largest shareholder, executive chairman <strong>Stefano Pessina</strong>, who <a href="https://www.benzinga.com/markets/equities/25/03/44185847/gary-black-says-walgreens-is-a-company-that-shouldnt-be-public-cites-largest-shareholders-role-in-10-billion-sycamore-deal" target="_blank" rel="noreferrer noopener">holds a 16.9% stake</a>.</p>
<p>The Financial Times, citing sources, writes that Stefano Pessina plans to nearly double his stake in the company to about 30% as part of its acquisition.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43104245/justice-department-accuses-walgreens-of-violating-drug-laws-in-opioid-epidemic-ignored-red-flags-in-opioid-crisis" rel="noreferrer noopener">Justice Department Accuses Walgreens Of Violating Drug Laws In Opioid Epidemic, Ignored Red Flags In Opioid Crisis</a></strong></p>
<p>The move signals Pessina&#8217;s deepening involvement in the company&#8217;s future, potentially ahead of a breakup of its various business units.</p>
<p>The FT report <a href="https://www.ft.com/content/ef898a28-ed96-45b5-baae-7569b8b778a3" target="_blank" rel="noreferrer noopener">added</a> that the transaction will allow Walgreens to restructure the struggling pharmacy giant. Walgreens is currently in a 35-day window to evaluate competing offers.</p>
<p>Pessina&#8217;s existing stake is worth approximately $2.1 billion. The deal&#8217;s complex financing structure is expected to allow Sycamore to potentially separate Walgreens&#8217; various business units into independent entities, reviving the possibility of selling Boots after <a target="_blank" href="https://www.benzinga.com/m-a/22/01/24860084/bain-capital-reportedly-eyeing-boots-uk-takeover-from-walgreens-report" rel="noreferrer noopener">previous failed attempts</a>.</p>
<p>Walgreens&#8217; market value once exceeded $100 billion following the 2014 merger of Walgreens and Alliance Boots, a deal orchestrated by Pessina. However, the company&#8217;s value has since fallen below $10 billion, facing mounting challenges from online competitors and shifting consumer habits.</p>
<p>Sources indicate that Pessina played a key role in securing the Sycamore deal as he sought a solution to Walgreens&#8217; declining stock price.</p>
<p>In January,&nbsp;Walgreens reported first-quarter sales of $39.46 billion, up 7.5% year over year (+6.9% on constant currency), beating the&nbsp;consensus of $37.28 billion, reflecting sales growth <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/42912519/walgreens-boots-alliance-stock-jumps-on-better-than-expected-q1-earnings-sticks-to-annual-profit-forecast" rel="noreferrer noopener">across all segments</a>.</p>
<p>Analysts estimate Walgreens&#8217; second quarter 2025 adjusted EPS of 53 cents, with sales of $37.9 billion. Wall Street forecasts 2025 adjusted EPS of $1.61 and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">sales of $151.6 billion</a>.</p>
<p><strong>Price Action:</strong> WBA stock is down 0.04% at $11.26&nbsp;at the last check Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/03/44375647/canadian-cannabis-sndl-achieves-break-even-free-cash-flow-for-2024" target="_blank" rel="noreferrer noopener">Canadian Cannabis SNDL Achieves Break-Even Free Cash Flow For 2024</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Large Cap

Health Care

General

Walgreens' Executive Chair Stefano Pessina Seeks To Strengthen Control With Nearly Double Stake

Regencell Bioscience Shares Halted On Circuit Breaker To The Downside, Stock Now Up 27.5%

<p>Guggenheim  analyst Michael Schmidt   downgrades Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) from Buy to Neutral and maintains the price target from $92 to $92.</p>


Downgrades

Guggenheim Downgrades Incyte to Neutral, Maintains Price Target to $92

<p>Truist Securities  analyst Ki Bin Kim   maintains Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) with a Hold and lowers the price target from $316 to $310.</p>


Truist Securities Maintains Hold on Public Storage, Lowers Price Target to $310

<p>Compass Point  analyst Casey Alexander   maintains TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) with a Neutral and lowers the price target from $8 to $7.25.</p>


TPVG

Compass Point Maintains Neutral on TriplePoint Venture Gwth, Lowers Price Target to $7.25

<p>Truist Securities  analyst Ki Bin Kim   maintains EPR Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>) with a Hold and raises the price target from $46 to $51.</p>


Truist Securities Maintains Hold on EPR Props, Raises Price Target to $51

<p>Guggenheim  analyst Curry Baker   initiates coverage on Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) with a Buy rating and announces Price Target of $12.</p>


Initiation

GENI

Guggenheim Initiates Coverage On Genius Sports with Buy Rating, Announces Price Target of $12

<p>Deep-pocketed investors have adopted a bearish approach towards Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MU usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Micron Technology. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 13% leaning bullish and 80% bearish. Among these notable options, 8 are puts, totaling $565,394, and 7 are calls, amounting to $354,723.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $70.0 to $120.0 for Micron Technology over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Micron Technology's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Micron Technology's substantial trades, within a strike price spectrum from $70.0 to $120.0 over the preceding 30 days.</p>
<h3>Micron Technology 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742306474_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.35</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$99.00</td>
<td>$210.8K</td>
<td>607</td>
<td align="right">543</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$4.85</td>
<td>$4.7</td>
<td>$4.65</td>
<td>$100.00</td>
<td>$93.6K</td>
<td>12.9K</td>
<td align="right">217</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$40.2</td>
<td>$39.8</td>
<td>$39.8</td>
<td>$70.00</td>
<td>$79.6K</td>
<td>865</td>
<td align="right">0</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$8.5</td>
<td>$8.4</td>
<td>$8.4</td>
<td>$100.00</td>
<td>$77.2K</td>
<td>14.1K</td>
<td align="right">110</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/17/27</td>
<td>$24.1</td>
<td>$23.1</td>
<td>$23.9</td>
<td>$100.00</td>
<td>$69.3K</td>
<td>105</td>
<td align="right">29</td>
</tr>
</tbody>
</table>
</p>
<h3>About Micron Technology</h3>
<p>Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.</p>
<p>After a thorough review of the options trading surrounding Micron Technology, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Micron Technology</h3>
<ul>
<li>With a volume of 1,886,364, the price of MU is down -1.9% at $101.15. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 2 days.</li>
</ul>
<h3>What The Experts Say On Micron Technology</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $128.33.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Micron Technology with a target price of $130.<br />
&#x2A; In a cautious move, an analyst from Wedbush downgraded its rating to Outperform, setting a price target of $125.<br />
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Micron Technology, which currently sits at a price target of $130. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Micron Technology options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

Micron Technology's Options Frenzy: What You Need to Know

<p>Deep-pocketed investors have adopted a bullish approach towards XPeng (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in XPEV usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for XPeng. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 66% leaning bullish and 11% bearish. Among these notable options, 4 are puts, totaling $150,960, and 5 are calls, amounting to $276,030.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $10.0 to $35.0 for XPeng over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in XPeng's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to XPeng's substantial trades, within a strike price spectrum from $10.0 to $35.0 over the preceding 30 days.</p>
<h3>XPeng Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742306468_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>XPEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.1</td>
<td>$2.73</td>
<td>$3.0</td>
<td>$35.00</td>
<td>$114.0K</td>
<td>6.6K</td>
<td align="right">404</td>
</tr>
<tr>
<td>XPEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.9</td>
<td>$5.35</td>
<td>$5.83</td>
<td>$18.00</td>
<td>$58.2K</td>
<td>277</td>
<td align="right">100</td>
</tr>
<tr>
<td>XPEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$3.45</td>
<td>$3.15</td>
<td>$3.3</td>
<td>$19.00</td>
<td>$46.2K</td>
<td>1.0K</td>
<td align="right">145</td>
</tr>
<tr>
<td>XPEV</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$4.6</td>
<td>$4.45</td>
<td>$4.5</td>
<td>$22.00</td>
<td>$45.0K</td>
<td>902</td>
<td align="right">337</td>
</tr>
<tr>
<td>XPEV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/17/25</td>
<td>$4.5</td>
<td>$4.15</td>
<td>$4.31</td>
<td>$22.00</td>
<td>$43.0K</td>
<td>902</td>
<td align="right">227</td>
</tr>
</tbody>
</table>
</p>
<h3>About XPeng</h3>
<p>Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 141,000 EVs in 2023, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.</p>
<h3>XPeng's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 6,931,461, the XPEV's price is down by -8.73%, now at $22.41. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 0 days.</li>
</ul>
<h3>Professional Analyst Ratings for XPeng</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $23.5.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Showing optimism, an analyst from UBS upgrades its rating to Neutral with a revised price target of $18.<br />
&#x2A; An analyst from Citigroup has elevated its stance to Buy, setting a new price target at $29. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest XPeng options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


A Closer Look at XPeng's Options Market Dynamics

<p>In the preceding three months, 5 analysts have released ratings for Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $97.6, a high estimate of $103.00, and a low estimate of $93.00. This upward trend is evident, with the current average reflecting a 6.32% increase from the previous average price target of $91.80.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742306466_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Globus Medical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$103.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$101.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Craig Bijou</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$97.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Globus Medical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Globus Medical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Globus Medical's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Globus Medical's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GMED/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Globus Medical analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Globus Medical</h2>
<p>Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.</p>
<h3>Understanding the Numbers: Globus Medical's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Globus Medical's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>6.61%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Globus Medical's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>4.03%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Globus Medical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>0.64%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Globus Medical's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.51%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Globus Medical's debt-to-equity ratio is below the industry average at <strong>0.13</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down Globus Medical: 5 Analysts Share Their Views

<p>Deep-pocketed investors have adopted a bearish approach towards Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in COST usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 13 extraordinary options activities for Costco Wholesale. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 23% leaning bullish and 53% bearish. Among these notable options, 7 are puts, totaling $461,953, and 6 are calls, amounting to $282,495.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $500.0 to $1460.0 for Costco Wholesale during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Costco Wholesale stands at 174.5, with a total volume reaching 230.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Costco Wholesale, situated within the strike price corridor from $500.0 to $1460.0, throughout the last 30 days.</p>
<h3>Costco Wholesale Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742306462_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>COST</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$24.5</td>
<td>$23.35</td>
<td>$24.5</td>
<td>$820.00</td>
<td>$98.0K</td>
<td align="right">341</td>
<td align="right">80</td>
</tr>
<tr>
<td>COST</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$25.0</td>
<td>$24.0</td>
<td>$24.0</td>
<td>$820.00</td>
<td>$96.0K</td>
<td align="right">341</td>
<td align="right">0</td>
</tr>
<tr>
<td>COST</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$15.3</td>
<td>$15.3</td>
<td>$15.3</td>
<td>$890.00</td>
<td>$76.5K</td>
<td align="right">658</td>
<td align="right">52</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$251.0</td>
<td>$249.0</td>
<td>$251.0</td>
<td>$660.00</td>
<td>$75.3K</td>
<td align="right">24</td>
<td align="right">3</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$257.8</td>
<td>$250.95</td>
<td>$250.95</td>
<td>$740.00</td>
<td>$75.2K</td>
<td align="right">19</td>
<td align="right">3</td>
</tr>
</tbody>
</table>
</p>
<h3>About Costco Wholesale</h3>
<p>Costco operates a membership-based, no-frills retail model predicated on offering a select product assortment in bulk quantities at bargain prices. The firm avoids maintaining costly product displays by keeping inventory on pallets and limits distribution expenses by storing its inventory at point of sale in the warehouse. Given its frugal cost structure, the firm is able to price its merchandise below that of competing retailers, driving high sales volume per warehouse and generating strong profits on thin margins. Costco operates over 600 warehouses in the United States and has over 60% share in the domestic warehouse club industry. Internationally, Costco operates another 280 warehouses, primarily in Canada, Mexico, Japan, and the UK.</p>
<p>Following our analysis of the options activities associated with Costco Wholesale, we pivot to a closer look at the company's own performance.</p>
<h3>Costco Wholesale's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 139,383, the COST's price is down by -1.21%, now at $905.51. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 72 days.</li>
</ul>
<h3>What The Experts Say On Costco Wholesale</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $1085.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Hold rating for Costco Wholesale, targeting a price of $995.<br />
&#x2A; Maintaining their stance, an analyst from Loop Capital continues to hold a Buy rating for Costco Wholesale, targeting a price of $1135.<br />
&#x2A; An analyst from Evercore ISI Group persists with their Outperform rating on Costco Wholesale, maintaining a target price of $1070.<br />
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for Costco Wholesale, targeting a price of $1125.<br />
&#x2A; An analyst from Telsey Advisory Group persists with their Outperform rating on Costco Wholesale, maintaining a target price of $1100. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Costco Wholesale options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


COST

Costco Wholesale's Options Frenzy: What You Need to Know

<p>Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $19.6, a high estimate of $28.00, and a low estimate of $16.00. Observing a downward trend, the current average is 35.1% lower than the prior average price target of $30.20. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742306455_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of Staar Surgical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Jon Young</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$17.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Staar Surgical. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Staar Surgical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Staar Surgical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Staar Surgical's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/STAA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Staar Surgical analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know Staar Surgical Better</h2>
<p>Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.</p>
<h3>Unraveling the Financial Story of Staar Surgical</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Staar Surgical's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-35.82%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Staar Surgical's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-69.92%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Staar Surgical's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-8.29%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Staar Surgical's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-6.54%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Staar Surgical's debt-to-equity ratio is below the industry average at <strong>0.1</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Comments

Veren

Veren (VRN) 옵션

Veren (NYSE:VRN) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌